NEW YORK (GenomeWeb) – Sygnis announced that it plans to raise up to €6.6 million ($8.1 million) through a private stock placement to help fund its planned acquisition of Australian reagent maker TGR Biosciences.

Sygnis said it will offer up to approximately 4.7 million newly issued shares to European institutional investors at a price of €1.40 per share. Proceeds from the offering will be used to acquire TGR, which Sygnis has agreed to buy for €10.4 million in cash and potentially convertible bonds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.